Image-guided Biopsy: What the Interventional Radiologist Needs to Know about PET/CT
Authors:
- Katsuhiro KobayashiKKKatsuhiro Kobayashi
- Peeyush BhargavaPBPeeyush Bhargava
- Shanker RajaSRShanker Raja
- Farbod NasseriFNFarbod Nasseri
- Hassan A. Al-BalasHAHassan A. Al-Balas
- Darryl D. SmithDSDarryl D. Smith
- Sharad P. GeorgeSGSharad P. George
- Meena S. VijMVMeena S. Vij
- 1 September 2012
- journal article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 32 (5) , 1483-1501
Abstract
Positron emission tomography (PET)/computed tomography (CT) with fluorine 18 fluorodeoxyglucose (FDG) is increasingly used in evaluation of oncology patients. Because PET/CT can demonstrate malignancy before morphologic changes are evident, application of PET/CT information to image-guided biopsy can facilitate early histologic diagnosis and staging. However, because FDG uptake is not specific to cancer, PET/CT findings may raise questions about whether uptake in a lesion is an indication for biopsy. To properly select patients for image-guided biopsy, interventional radiologists should be familiar with the biologic significance of FDG uptake and various causes of false-positive uptake. PET/CT images may also become a source of confusion in the interpretation of biopsy results. Various causes of false-positive and false-negative FDG uptake need to be considered, especially when there is a discrepancy between biopsy results and PET/CT findings. False-negative FDG uptake can result from cancers that are too small to be observed or not FDG avid. False-positive FDG uptake can be due to underlying inflammation from recent treatment. Conversely, complete resolution of FDG uptake in a treated lesion does not necessarily indicate absence of viable cells. When questions about PET/CT findings arise in the context of image-guided biopsy, discussion with experienced nuclear imaging physicians is essential.Keywords
This publication has 24 references indexed in Scilit:
- Clinical significance of diffusely increased splenic uptake on FDG-PETNuclear Medicine Communications, 2009
- False-Positive FDG PET Uptake−the Role of PET/CTEuropean Radiology, 2005
- Whole-body PET/CT: Spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patientsNuclear Medicine Communications, 2005
- Spectrum of Thymic Uptake at18F-FDG PETRadioGraphics, 2004
- PET-CT Fusion Imaging in Differentiating Physiologic from Pathologic FDG UptakeRadioGraphics, 2004
- Diaphragmatic and Crural FDG Uptake in Hyperventilating Patients: A Rare Pattern Important to RecognizeClinical Nuclear Medicine, 2004
- 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammationSeminars in Nuclear Medicine, 2002
- Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.Journal of Clinical Oncology, 1998
- Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational, and Mutational Events That Lead to a Critical Role for Type II HexokinaseJournal of Bioenergetics and Biomembranes, 1997
- Glycogenolysis versus glucose transport in human granulocytes: differential activation in phagocytosis and chemotaxisBlood, 1982